Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Active, not recruiting · NCT03534323 · Registry updated 2026-03-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Richter transformation, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-23 | NCT03534323 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Secura Bio, Inc. | 4 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Berkshire Medical Center | Pittsfield | United States | 5 |
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Boston Medical Center | Boston | United States | 200 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Northern Light Eastern Maine Medical Center | Brewer | United States | 1 |
| University of Miami- Sylvester Comprehensive Cancer Center | Miami | United States | 2 |